Reply to Suthar et al

Affiliations

¹ Bio Analytical Research Corporation and Lancet Laboratories, Johannesburg, South Africa.
² HIV Research Branch, Rockville, Maryland.
³ Drug Development and Clinical Sciences Branch, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
⁴ Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pennsylvania.

Comment

Carole L Wallis et al. J Infect Dis. 2019.

. 2019 Jan 29;219(4):673-674.

doi: 10.1093/infdis/jiy558.

¹ Bio Analytical Research Corporation and Lancet Laboratories, Johannesburg, South Africa.
² HIV Research Branch, Rockville, Maryland.
³ Drug Development and Clinical Sciences Branch, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
⁴ Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pennsylvania.

No abstract available

Comment on

Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.
Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW. Wallis CL, et al. J Infect Dis. 2017 Dec 1;216(suppl_9):S851-S856. doi: 10.1093/infdis/jix409. J Infect Dis. 2017. PMID: 29207000 Free PMC article. Review.
Antimicrobial Resistance and Substandard and Falsified Medicines: The Case of HIV/AIDS.
Suthar AB, Coggin W, Raizes E. Suthar AB, et al. J Infect Dis. 2019 Jan 29;219(4):672-673. doi: 10.1093/infdis/jiy557. J Infect Dis. 2019. PMID: 30307565 Free PMC article. No abstract available.

1. Gandhi M, Gandhi RT, Stefanescu A, et al. ; A5321 Team Cumulative antiretroviral exposure measured in hair is not associated with measures of HIV persistence or inflammation among individuals on suppressive ART. J Infect Dis 2018; 218:234–8. - PMC - PubMed
1. President’s Emergency Plan for AIDS Relief. Controlling the epidemic: Delivering on the promise of an AIDS-free generation PEPFAR 3.0 https://www.pepfar.gov/documents/organization/234744.pdf. Accessed 24 September 2018.
1. Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Achieving viral suppression in 90% of people living with human immunodeficiency virus on antiretroviral therapy in low- and middle-income countries: progress, challenges, and opportunities. Clin Infect Dis 2018; 66:1487–91. - PMC - PubMed
1. Gupta RK, Gregson J, Parkin N, et al. . HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis 2018; 18:346–55. - PMC - PubMed
1. Kazooba P, Mayanja BN, Levin J, Masiira B, Kaleebu P. Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy-evidence from a prospective cohort study in rural South-Western Uganda, 2004–2011. Pan Afr Med J 2018; 29:191. - PMC - PubMed